Subject Index

Subject Index

18-fl uoro-2-deoxyglucose 41

67

Ga scintigraphy 166

A

ACOP+ regimen 88 acute B-cell leukemia 149

acute lymphoblastic leukemia 85, 155, 162, 200, 261 acyclovir 240

adenosine deaminase 247 AIDS 144, 243

ALCL

(see anaplastic large cell lymphoma) ALK 177

alkylating agent 50, 51, 59, 67, 264, 265 allogeneic transplantation 167, 168

allopurinol 163 ALPS

(see Autoimmune lymphoproliferative syndrome) amenorrhea 266

anaplastic large-cell lymphoma 17, 25, 175 ALK 113–118

ALK staining 113–115, 118 alternative translocations 116–118 anti-ALK IgG antibodies 192 bone involvement 177

bone marrow transplantation 189 CD30 antigen 175

cis-retinoic acid 190 clonal nature 177 cytogenetics 113, 114, 116 cytokine production 181 diff erential diagnosis 117 EBV 117

extranodal involvement 178 immunohistochemical stain 113–115 immunotherapy 190

incomplete tumor resolution 187 lymphohistiocytic variant 176 –

– –

– – – – – – – – – – – – – – – – – –

lymphomatoid papulosis 177 malignant histiocytosis 175 molecular mechanisms 117–118 morphology 112–113

neutrophil-rich subform 176 NPM 116–118

pathology 112–117

primary cutaneous 113, 117, 176 sarcomatoid form 176

second-look surgery 187 signal transduction 118 small-cell variant 176 small interfering RNAs 191 subclassifi cation 176 T-cell response 192 tyrosine kinase activity 118 tyrosine kinase inhibitors 191 vinblastine 190

Ann Arbor staging 23, 42, 43, 148 Staging 23

anthracycline-induced cardiotoxicity 46 anthracyclines 53, 156, 262, 205 antiferritin 79

antithymocyte globulin 239 apoptosis 10, 74

APO regimen 160 Ara-C 152, 154, 156, 159

intrathecal 154 Ara-G 208 ASCR

(see autologous hematopoietic stem cell rescue) asplenia 267

AT

(see ataxia telangiectasia) ataxia telangiectasia 246, 249 ATG

(see antithymocyte globulin) atherosclerotic heart disease 49 atypical Burkitt lymphoma (aBL)

(see Burkitt-like lymphomas) –

– – – – – – – – – – – – – – – – – –

–

–

–

–

–

autoimmune disorders 38

autoimmune lymphoproliferative syndrome 248 autologous hematopoietic stem cell rescue 70 autologous stem cell rescue (ASCR) 71 autologous stem cell transplantation 260 axillary lymph nodes 57

azoospermia 58, 265, 266 azotemia 163

B

B-cell 10, 11, 22, 24, 234 lymphoid tissue 234 lymphoma 22, 24 neoplasm 22

B-cell lymphoma 19, 142, 144, 146, 147, 151, 161, 164, 237 chemotherapy 151

HIV infection 144 imaging studies 144

nuclear medicine scanning 146 prognostic factor 163

radiotherapy 161

results of various protocols in the treatment 165 risk groups 157

staging classifi cations 148 staging studies 150 surgical resection 161 Tumor Burden 163 B-cell proliferation 245

B-cell specifi c activator protein 17 bacterial adenitis 199

BACT regimen 88

benign lymphoid hyperplasia 37 benzodiazepines 59

Berlin-Frankfurt-Munster group (BFM) 149 BIKE regimen 152

biopsy 40 BL

(see Burkitt Lymphoma) bleomycin 60, 73

bleomycin-associated pulmonary fi brosis 263 bleomycin-induced pulmonary toxicity 46 BLL

(see Burkitt-like lymphomas) blood or marrow transplant (BMT) 236 blood or marrow transplantation 233, 239 blood urea nitrogen 202

BMT

(see blood or marrow transplantation) –

– – – – – – – – – – – – – –

–

–

–

bone manifestations 179 bone marrow 23, 86

bone marrow disease 146, 149 Bone marrow involvement 42 bone marrow transplantation 71 bone mineral density 264 bortezomib 75, 76, 77

pediatric patients 77 relapsed/refractory HL 77 breast cancer 49

BSAP

(see B-cell specifi c activator protein) B symptoms 50

bulk disease 58, 78, 87 BUN

(see blood urea nitrogen) Burkitt 237

Burkitt-like lymphoma 142, 144, 237 Burkitt lymphoma 15, 85, 101–107, 244

atypical Burkitt lymphomas 102, 104 Burkitt-like lymphoma 102

Burkitt leukemia ALL-L3 102 c-myc transformation 106–107 cmyc 103–107

cmyc and cell cycle progression 106–107 cmyc and histone deacetylation 106 cmyc and metabolic pathways 107 cytogenetics 103–104

detection of translocations 104 EBV 107

Endemic Burkitt Lymphomas 101–102, 107 genetic dysregulution 106

immunophenotypic 102, 105 molecular mechanisms 104–107 morphology 101–103

pathology 101–104

Sporadic Burkitt Lymphomas 101–102, 107 translocational achvahen 106

C

c-myc oncogene 244 C-reactive protein 37 CAD

(see coronary artery disease) cardiac disease 262

cardiac toxicity 261 cardiotoxicity 209, 262 cardiovascular disease 268 –

–

–

–

– – – – – – – – – – – – – – – – – – –

–

Castleman´s disease 26 CCSS

(see Childhood Cancer Survivor Study) CDKs

(see cyclin-dependent kinases) centroblastic lymphoma 165 cervical adenopathy 199 cervical nodal disease 36 CGH

(see comparative genomic hybridization) Chediak-Higashi syndrome 248

chemokine 13 receptor 13 chemotherapy 2, 45

alkylating agent 4 bleomycin 4

combination chemotherapy 3 dose-intensive regimens 49

long-term eff ects on children and adolescents 49 MOPP 2, 3

multiagent chemotherapy 4 re-induction 68

chest CT scan 145 chest X-ray 145

Childhood Cancer Survivor Study 259 Children´s Oncology Group (COG) 269 CHL

(see classical Hodgkin lymphoma) CHOP chemotherapy 204

CHS

(see Chediak-Higashi syndrome) classical Hodgkin lymphoma 9 clinical trial 2

low-dose radiotherapy in combination with combination chemotherapy 3

CLIP

(see Cytoplasmic linker protein) CNS disease 154, 159, 162, 208

prevention 159 prophylaxis 162 treatment 208 CNS prophylaxis 155, 205 CNS therapy 148, 203 Coley´s toxin 86

combination chemotherapy 45, 49 combined modality therapy 3

low, intermediate, and high 4

low-dose radiotherapy in combination with combination chemotherapy 3

risk-adapted treatment 4 –

–

–

– – – – – – – – –

–

–

–

– – – –

– – –

common variable immunodefi ciency 246 comparative genomic hybridization 14 COMP regimen 155, 203

computed tomography 41, 145 of the abdomen 145 COM regimen 154 congestive heart failure 262 COPAD protocol 88 coronary artery disease 261 corticosteroids 157, 264 cranial nerve palsies 148, 202 cranial radiotherapy 264 CRP

(see C-reactive protein) cryopreservation 267 CSF pleocytosis 148 CT

(see computed tomography) CTX

(see cyclophosphamide) CVID

(see common variable immunodefi ciency) cyclin-dependent kinases 14

cyclophosphamide 46, 53, 87, 151, 152, 205, 242, 260, 265 cyclosporin 248

cyclosporine 240 cytarabine 204 cytochrome c 11 cytogenetics 142 cytokines 13, 24 cytoplasm 79

cytoplasmic linker protein 10 cytosine arabinoside 73 cytotoxicity 242 cytotoxic therapy 234

D

DAL-HD-90 trial 44, 56 daunorubicin 156 DECAL regimen 167 dental caries 267 dental hygiene 267 depression 268 dexamethasone 77 dexrazoxane (DZR) 262

diff use large-cell lymphoma (DLCL) 244 diff use large B-cell lymphoma 107, 142, 143, 238

activated B-Cell gene expression profi le 111, 112 –

–

– – –

–

BCL-6 109

BCL-6 mutation 110–111 BCL-6 translocations 109–110

constitutive NK-KB pathway activation 112 cytogenetic 107, 109–112

gene expression profi ling 111–112

germinal center gene expression profi le 111–112 immunophenotype 108–109

molecular genetics 107–110 morphology 107–110 pathology 107–109

disseminated intravascular coagulation 181 DLBCL

(see diff use large B-cell lymphomas) DNA transcription 74

donor leukocytes 241

dose-limiting toxicity (DLT) 69 Downey cells 235

DOX

(see doxorubicin)

doxorubicin 46, 60, 156, 204, 261, 263

E EBER

(see EBV-encoded ribonucleotides) EBER-positive cells 238

EBNA

(see Epstein-Barr nuclear antigens) EBV

(see Epstein-Barr Virus)

EBV-associated hemophagocytic lymphohistiocytosis 247 EBV-encoded ribonucleotides 15, 16, 18

EBV-encoded RNAs (EBERs) 234 EBV-HLH

(see EBV-associated hemophagocytic lymphohistiocytosis)

EBV-LPD

(see EBV-lymphoproliferative disorders) EBV-lymphoproliferative disorders 77 EBV infection 40, 44

EFS

(see event-free survival) EMA

(see epithelial membrane antigen) enalapril 263

endothelium 8 epipodophyllotoxin 67 epithelial membrane antigen 18 Epstein-Barr nuclear antigens 15, 234

Epstein-Barr Virus 14, 37, 77, 143, 233, 234, 244 –

– – – – – – – – – –

–

–

–

– –

–

–

– –

erebrospinal fl uid pleocytosis 147 erythrocyte sedimentation rate 37 ESR

(see erythrocyte sedimentation rate) etoposide 54, 59, 68, 156, 260 event-free survival 46 extrinsic pathway 10

F FADD

(see Fas–associated death domain) fas-associated death domain 10 fascin 18

FDG

(see 18-fl uoro-2-deoxyglucose) fertility 265

fi brosis 19, 22 fi brous obliteration 20 FICTION 14 FIM

(see fulminant infectious mononucleosis) FK506 (tacrolimus) 240

Flow cytometry 18 fl udarabine 77

follicular lymphoma 144

fulminant infectious mononucleosis 247

G

gabapentin 60 gallium-67 146 ganciclovir 240 gemcitabine 73

maximally tolerated dose 73 gene expression 14

gene expression profi ling 143 germ cell aplasia 265 germinal center (GC) 244 gonadal toxicity 59 graft -versus-host disease 70 graft -versus-lymphoma 72 graft vs host disease (GVHD) 238 granulocytopenia 69

granulomas 21 GVHD

(see graft -versus-host disease) GVL

(see graft -versus-lymphoma) –

–

–

–

–

–

–

H HAART

(see highly active antiretroviral therapy) haemophilus infl uenzae 39

hematopoietic stem cell transplantation 54, 234 hemophagocytosis 180

hepatosplenic T-Cell lymphoma 227 hepatosplenomegaly 245

hepatotoxicity 73 heterophil antibodies 235

highly active antiretroviral therapy 243 histopathology 1

Classical Hodgkin lymphoma 2 granuloma 2

lymphoctic/histiocytic diff use 2 lymphocyte-rich 2

lymphocyte depletion 2 lymphocytic 2

lymphocytic/histiocytic nodular 2 lymphocytic depletion 2

mixed 2

mixed cellularity 2

nodular lymphocyte predominant 2 nodular sclerosis 2

paragranuloma 2 predominance 2 reticular 2 rye 2 sarcoma 2 WHO 2 histoplasmosis 40 HIV 245

seronegative children 245 HIV infection 144

HL

(see Hodgkin lymphoma)

Hodgkin lymphoma 7, 16, 23, 25, 35, 36, 43, 237, 259 Chemotherapy regimens 47

children 43

children and adolescents 35 clinical staging 149 cytokine production 38 diff erential diagnosis 25 EBV association 23 HIV Infection 23 immune profi les 39

immunohistochemical fi ndings 16 interfollicular 21

international Database 44 intrathoracic 36

–

– – – – – – – – – – – – – – – – – –

–

– – – – – – – – – – – – – –

late eff ects 259 mixed cellularity 20 mortality 268

multimodality therapy 259 pathology 7

pediatric 35, 67

– chemotherapy side-eff ects 59 – combination chemotherapy 49 – low-risk disease 51

– modern treatment 46 – multimodality therapy 56 – risk-adapted approach 51 pediatric trials 45

prognostic factors 43 relapsed/refractory disease 68 salvage approaches 79 Hodgkin Reed-Sternberg 9 Hodgkin Reed-Sternberg cells 16 hormonal function 265

HRS

(see Hodgkin Reed-Sternberg) HSCT

(see hematopoietic stem cell transplantation) human herpes virus-8 (HHV-8) 234

human immunodefi ciency type 1 (HIV-1) infection 233 human immunodefi ciency virus (HIV) 40

human immunodefi ciency virus type 1 (HIV) 242 human papilloma virus (HPV) 234

humeral head blocks 57 humoral immunity 39 hybrid chemotherapy 53 hyperkalemia 163

hyperphosphatemia 163, 203 hypersensitivity 25

hyperthyroidism 264 hyperuricemia 203 hypocalcemia 163 hypoplasia 45 hypothyroidism 264 hypoxanthine 163

I IAP

(see inhibitors of apoptosis) IF

(see interferon) ifosfamide 69, 156 Ig

(see immunoglobulin) –

– – – – – – – – – – – – – – –

– –

– –

–

IkB

(see inhibitors of kB) IL

(see interleukin) IM

(see infectious mononucleosis) immune thrombocytopenia (ITP) 38 immunodefi ciency syndromes 40 immunoglobulin 9, 10, 19, 245

heavy (IgH) 10 immunohistochemistry 24 immunomodulation 71

immunosuppression 151, 240, 241, 242 immunotherapy 71

infectious mononucleosis 15, 25, 40 infectious mononucleosis (IM) 235 infertility 209, 266

inhibitors of apoptosis 11 inhibitors of kB 11

kinase (IKK) complex 11 in situ hybridization 18 interferon 13

interferon-α 241 interferon-γ 71 interleukin 13 interleukin-2 71 interstitium 79 intrinsic pathway 11

intussusception of the small bowel 147 involved-fi eld radiation 49, 50, 54, 58, 162, 204

low-dose 50 ISH

(see In situ hybridization) IκB kinases (IKK) 74

J Jak

(see Janus kinase) Janus kinase 12 jaw tumor 146

K

Kaposi´s sarcoma (KS) 243 Ki-67 144

known tumor suppressor genes 238 –

– –

–

–

– –

–

L L&H cells 22 L-asparaginase 204 lacunar cells 16 Langhans´s giant cells 8 large B-cell lymphoma 17 latent membrane proteins 15 LBL

(see T-lymphoblastic lymphoma) LDHL

(see Lymphocyte Depleted HL) leukemia 25, 86, 87

L2 regimen 87 leukemogenesis 53 Lhermitte´s syndrome 61 LRCHL

lymphocyte-rich classical Hodgkin lymphoma 10 lung blocks 57

lymphadenopathy 36, 39, 40 supraclavicular 36 lymph node bulk 51 lymph node distribution 56 lymph nodes 24, 36

lymphoblastic lymphoma 167, 199, 201, 202 8p11 120–124

anesthesia/sedation 201

B-lymphoblastic Lymphoma 119–120

B-lymphoblastic lymphoma molecular mechanisms 126 cytogenetics 119–121, 124–127

gallium seen 202 gene rearrangements 121 HOX 121, 123

immunophonotype 119, 121 lineage infi delity 121 LMO 121–123 LYL1 121–123

microarray analysis 126–127

molecular mechanisms of lymphomagenesis 121–127 morphology 120

NOTCH1 121–127 nuclear imaging studies 201 pathology 119–121 PET scans 202

precursor T-lymphoblastic lymphoma with eosinophilia 120–121

proto-oncogenes 121–126 relationship to ALL 119–120 T-cell receptor (TCR) receptor 121 T-lymphoblastic Lymphoma 119–121 –

– –

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

–

T-lymphoblastic lymphoma molecular mechanisms 121–126

TAL1 121–123 treatment 202

lymphocyte-rich classical Hodgkin lymphoma 10 lymphocyte depleted HL 22

lymphocyte depletion 20

lymphocyte predominant Hodgkin’s disease 22 lymphocytic leukemia 22

lymphoid neoplasms 25 lymphoid tumors 86

lymphomatoid papulosis 26, 221 lymphopenia 37

lymphoproliferative disorder (LPD) 248 lymphosarcoma 86

M MALT 142

MALT-associated lymphomas 144

Mediastinal (thymic) large B-cell lymphoma 26 mediastinal adenopathy 44

Megavoltage energies 59 melphalan 152

meningoencephalitis 247

methotrexate 54, 87, 150, 151, 156, 159, 204, 261, 264 High-dose 156

intrathecal 261 MHC class II molecules 10 minimal residual disease 209 miscarriage 266

mitochondrial outer membrane 11 mixed cellularity HL 20, 37 MLBCL

(see Mediastinal (thymic) large B-cell lymphoma) molecular techniques 142

MOM

(see mitochondrial outer membrane) monitoring 269

MRD

(see minimal residual disease) MRI 145

MTX

(see methotrexate)

mucosa-associated lymphoid tissue (MALT) 167, 244 multiagent 35

multileaf collimation 58

myc-immunoglobulin 142, 143, 166, 168 mycosis fungoides 216

– – –

– –

–

–

–

–

MYC protein 164 myeloma 237

myelosuppression 59, 73 myelosuppressive 54 myocarditis 247

N

nasopharyngeal carcinoma 26 natural killer (NK) cells 235 natural killer cell cytotoxicity 39 NCPE

(see noncardiogenic pulmonary edema) neoplastic disorders 246

neuraxis radiation 162 neurocognitive toxicity 261 neutropenia 69, 166 NF-kappaB 11 NF-кB

(see nuclear factor kappa B) NHL

(see non-Hodgkin lymphoma) nitrogen mustard 86

NLPHL

(see nodular lymphocyte predominant Hodgkin lymphoma)

NLRCHL

(see Nodular Lymphocyte Rich CHL) NMZL

(see nodal marginal zone lymphoma) nodal marginal zone lymphoma 168

nodular lymphocyte predominant Hodgkin lymphoma 9, 22, 144

nodular lymphocyte Rich CHL 21 nodular scabies 222

nodular sclerosis 19 nodular sclerosis HL 37

non-Hodgkin lymphoma 40, 85, 203, 243, 259 late eff ects 259

multimodality therapy 259 T-cell phenotype 24

non-Hodgkin lymphomas (NHLs) 91, 142 anaplastic large-cell lymphoma 112–118 Burkitt lymphomas 101–107

cytogenetics 95–100

– genes involved in translocations 98, 101 – translocations in pediatric NHL 97, 101 cytogenetics techniques 98

diff use large B-cell lymphoma 107–112 –

– –

–

– –

–

–

–

–

–

–

–

–

–

–

Immunophenotyping – antigen epitopes 96 – fraw cytometry 94

– immunohistochemistry 94–95 lymphoblastic lymphoma 119–127 molecular pathogenesis 101 molecular testing 100 – FISH 100, 101 – PCR 100, 101 pathology

– ancillary testing 93–101 – morphology 93–94

– tissue handling and allocation 93–94 pediatric vs adult 92

relapsed/refractory disease 68 St Jude staging system 149 treatment 155

WHO Classifi cation 100, 101

non-myeloablative stem cell transplantation 72 noncardiogenic pulmonary edema 73 NPM gene 177

NSAL

(see Nodular Sclerosis HL) NSHL 20

syncytial variant 20 NST

(see non-myeloablative stem cell transplantation) nuclear factor kappa B 11, 74

O

oligospermia 265 Omenn´s syndrome 247 oncogenes 238

oocytes 267

ophthalmoplegia 146 organ toxicity 241 orthopnea 200 OS

(see overall survival) osteonecrosis 264 osteopenia 264 osteoporosis 264 overall survival 68 –

– – – – – – – – – – – – – – – – –

– – –

–

P

paragranuloma 9 paraplegia 147 PCR

(see polymerase chain reaction) Pediatric Oncology Group (POG) 87 Pediatric Oncology Group (POG) study 50 pediatric patients 35

PEL

(see primary eff usion lymphoma) Pel-Epstein fever 37

penicillin 267 pericardiectomy 262

peripheral blood stem cell (PBSC) 239 Peripheral T-cell lymphomas 26 PET

(see positron emission tomography) PET-CT 41

imaging 41 PET scanning 166 pharyngeal tumor 147

phosphatidyl inositol kinase (PIK) family 249 pityriasis lichenoides et varioliformis acuta 222 plasmacytoma 237

pleural eff usion 201, 245 PMBL

(see primary mediastinal large B-cell lymphoma) PNP

(see purine nucleoside phosphorylase defi ciency) POG protocols 156

polymerase chain reaction 19, 236 popcorn cells 22

positron emission tomography 41, 178 post-transplant lymphoproliferative disease 236 precursor B-cell neoplasms 200

precursor T-cell lymphoblastic lymphoma 200, 208 Relapse 208

precursor T-cell neoplasms 200 prednisone 242

premature ovarian failure 266

primary cutaneous anaplastic large-cell lymphoma 224 anaplastic 225

CD30 antigen 225 cell 225

cutaneous 225 large 225 lymphoma 225 primary 225

primary eff usion lymphoma 243 –

–

– –

– –

–

–

–

–

–

–

–

–

primary mediastinal large B-cell lymphoma 143 procarbazine 46

proteasome inhibition 76 pruritus 37

PTCL

(see Peripheral T-cell lymphomas) PTLD

(see Post-transplant lymphoproliferative disease) pulmonary fi brotic disease 263

pulmonary toxicity 263

purine nucleoside phosphorylase defi ciency 247 pyogenic bacterial lymphadenitis 39

R

radiation 50, 61 Side-Eff ects 61 radiation therapy 57

dose considerations 58 pelvic dose 58

Radiation Th erapy Oncology Group (RTOG) 269 radiotherapy 1, 161, 261

cranial 261 extended fi eld 2

extended fi eld radiation 3 involved-fi eld radiation 4 involved fi eld 2

low-dose 4 thoracic 261 RANTES 13 re-induction 68 re-induction regimen 68 REAL

(see Revised European-American Lymphoma) Reed-Sternberg 17

Reed-Sternberg cell 16

reproductive endocrinology 266 respiratory distress 202 restin 10

retinoblastoma 260

revised european-american lymphoma 22 rituximab 78, 167, 239, 240, 241

RS

(see Reed-Sternberg cell) –

–

– – –

– – – – – – –

–

–

S

salvage strategies 72 sarcomatoid 22 SCID

(see Severe combined immunodefi ciency) secondary acute myeloid leukemia (s-AML 53 second malignant neoplasms 260

sequelae in 3 breast cancer 3 cardiovascular disease 3 growth 3

growth and development 3 hypothyroidism 4 infectious complications 4 non-Hodgkin lymphoma 3 psychosocial 4

pulmonary toxicity 4 secondary leukemia 3 secondary solid tumor 3 sterility 4

serum alkaline phosphatase 42 serum LDH 157

serum markers 164

severe combined immunodefi ciency 247 severe graft -vs-host disease (GVHD) 240 Sezary syndrome 217

SFOP experience 164

signal transducer and activator of transcription 12 skeletal metastases 42

skin lesions 179 SMNs

(see second malignant neoplasms) soft -tissue involvement 179

solid organ transplantation 233, 236, 240 somatic distress 268

SOT

(see solid organ transplantation) spermatogenesis 265

spermatozoa 266 splenectomy 50, 267 splenic nodules 8 staging 2

Ann Arbor 2 bone marrow biopsy 4 chest radiograph 4 clinical stage (CS) 2 clinical staging 4 CT 2, 4

extranodal organ or site involvement (E) 2 –

– – – – – – – – – – – –

–

–

–

–

–

–

–

–

–

pathologic stage (PS) 2

positron emission tomography 4 surgical staging and splenectomy 4

surgical staging with laparotomy and splenectomy 3 systemic symptoms (A or B) 2

staphylococcus aureus 18 staphylococcus epidermidis 71 STAT

(see signal transducer and activator of transcription) stem cell support 208

stem cell transplantation 167 stillbirths 266

subcutaneous panniculitis-like T-Cell lymphoma 226 superior vena cava (SVC) syndrome 202

swelling lymph nodes 202

T T-cell

immune defi cits 38

T-cell-rich B-cell lymphoma 143

T-cell/histiocyte rich large B-cell lymphoma 26 T-cell depletion 239

T-cell immunity 239 T-cell lymphoma 19 T-cell markers 19 T-cell receptor 19

T-lymphoblastic lymphoma 26 tacrolimus (FK506) 248 TBI

(see total body irradiation) TCD

(see T-cell depletion) T cells 72, 249

double-negative 249 TCHRLBCL

(see T-cell/histiocyte rich large B-cell lymphoma) TCR

(see T-cell receptor) TCRBL

(see T-cell-rich B-cell lymphoma) teniposide 68, 204

testicular disease 167 testosterone 265 thioguanine 155 thiotepa 260 thoracentesis 200 thrombocytopenia 79 thymomas 26 –

– – – –

–

–

– – – – – –

thyroid dysfunction 264 TIL

(see Tumor infi ltrating lymphocytes) TNF-related apoptosis-inducing ligand 76 TNFR

(see tumor necrosis factor receptor) total body irradiation 70

toxoplasmosis 40 TRAF

(see Tumor necrosis factor receptor-associated factors) TRAIL

(see Tumour necrosis factor-related apoptosis-inducing ligand) transforming growth factor (TGF)-ß 13 treatment toxicity 51

TRIKE regimen 152 tuberculosis 8

tubular obstruction 163

tumor infi ltrating lymphocytes 14 tumor lysis syndrome 203

tumor necrosis factor (TNF) receptor family 78 tumor necrosis factor receptor 12, 15

tumor necrosis factor receptor-associated factors 12 tumour necrosis factor-related apoptosis-inducing

ligand 10

U

ubiquitin proteasome pathway 75 UPP

(see ubiquitin proteasome pathway) uricolytic agents 203

uricosemia 162 uricozyme 203

V

varicella zoster infections 59 VCR

(see VCR) vinca alkaloids 60 vinca alkaloids 69 vincristine 151 vinorelbine 69, 73

viral capsid antigen (VCA) antibodies 235 –

–

– –

–

–

W

Waldeyer´s ring 40, 41 WAS

(see Wiskott-Aldrich syndrome) Whole-lung irradiation 57

Wiskott-Aldrich syndrome 246, 247 protein (WASP) 247

X

X-linked hyper IgM syndrome 248

X-linked lymphoproliferative disease (XLP) 246 X-linked thrombocytopenia 247

xanthine 163 xerostomia 267 XHIM

(see X-linked hyper IgM syndrome) XLT

(see X-linked thrombocytopenia)Y –

–

– – –

Z

zidovudine 243